Doravirine/Islatravir (Idvynso) for HIV
Doravirine/Islatravir (Idvynso) for HIV
August 31, 2026 (Issue: 1762)
The FDA has approved Idvynso (Merck), a once-daily
fixed-dose combination of the non-nucleoside reverse
transcriptase inhibitor (NNRTI) doravirine and the first-in-
class nucleoside reverse transcriptase translocation
inhibitor (NRTTI)...more
- Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://bit.ly/4xuX1ma. Accessed August 11, 2026.
- C Orkin et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet 2026; 407:599. doi:10.1016/s0140-6736(25)01945-2
- AE Colson et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet 2026; 407:611. doi:10.1016/s0140-6736(25)01948-8
- V Williams and TJ Cory. Doravirine/islatravir for the treatment of HIV. Expert Opin Pharmacother 2025; 26:9. doi:10.1080/14 656566.2024.2440000
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. August 5, 2026. Reprinted with permission by First Databank, Inc. All rights reserved. ©2026. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Doravirine/Islatravir (Idvynso) for HIV
Article code: 1762b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
